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 new  era  in psoriasis  and  psoriatic  arthritis
herapy: new  mechanisms  of action  and  the
ntroduction of  biogeneric  drugsma  nova  era  na  terapia  em  psoríase  e  artrite  psoriática:  novos
ecanismos  de  ac¸ão  e  a  introduc¸ão  de  biossimilaresnterleukin-17 is a proinﬂammatory cytokine that acts by
ncreasing the expression of chemokines that recruit mono-
ytes and neutrophils to the site of inﬂammation. Produced by
elper T cell subtypes and induced by other interleukin (IL23),
L17 initiates its function by joining itself to a cell membrane
eceptor (IL17R).1 The neutralization of this function by the
lockage of this union to the receptor, or by the administration
f a speciﬁc antibody against interleukin, entails the possibil-
ty of a new biological treatment of autoimmune diseases such
s Psoriasis and Psoriatic Arthritis.2,3
The introduction of a new biological, with a new mech-
nism of action, means that the history of biological
herapies for psoriasis and other autoimmune diseases will
e re-written. The neutralizing monoclonal antibody, IL17
secukinumab), should be approved by ANVISA by the end
f 2005 or beginning of 2006.2 US Food and Drug Administra-
ion (FDA) recommended an almost unanimous approbation
f secukinumab for the treatment of psoriasis; and this drug
as approved months ago by the European Medicines Agency
EMA) under the trade name Cosentyx. Two other biological
gents should become widely available soon: Ixekizumab and
rodalumab, a anti-IL-17 receptor monoclonal antibody. What
raws more  attention in the studies which led to the approval
f anti-IL17 is that those papers that carried out head-to-head
omparisons between etanercept and ustekinumab – which
re part of the standard therapy with biological agents for
soriasis – show that anti-IL17 features have superior clinical
fﬁcacy versus anti-TNF and anti-IL12-23.
In a study including 1307 patients receiving secukinumab,
he response to anti-IL17 was more  robust when compared to
tanercept. When compared to ustekinumab after 4 months in
 phase III study, most of patients achieved PASI 90 in a more
igniﬁcant percentage, when compared to the group treated
nly with ustekinumab. Similarly to what seems to occur in
atients with rheumatoid arthritis, small molecules shouldalso play a role in the treatment of psoriasis and psoriatic
arthritis. This is indeed the case of Apremilast, an inhibitor of
phosphodiesterase and modulator of cAMP levels, which has
recently been approved by FDA. One aspect that brought some
controversy regarding the analysis of the clinical studies was
that, in the approval of this agent, body mass was not consid-
ered (patients with psoriasis tend to be obese when compared
to individuals of the same age but without psoriasis). The other
aspect to consider is that, even not being a biological agent, but
a synthetic one, pharmaceutical companies are introducing
the drug on the market with prices similar to those practiced
for biological agents.4–10 IL17 is a proinﬂammatory cytokine
that plays an important role in perpetuating the psoriatic
plaque. The receptor for IL17 can be found on the surface of
keratinocytes, and its blockage reverses the histopathology of
the psoriatic lesion. With anti-IL17, it is possible to obtain an
almost complete whitening of skin lesions, besides a simul-
taneous improvement of the associated arthritis, especially
if this is the ﬁrst biological used. Similarly to what occurs
in rheumatoid arthritis and psoriasis, after 3 years of treat-
ment, less than half of the patients who had been initially
beneﬁted with favorable responses still present convincing
clinical responses. This phenomenon, also known as “biolog-
ical fatigue”, seems to be common in rheumatic patients and
with plaque psoriasis.
Adverse effects of anti-IL17 are more  infectious in nature,
but do not appear to be an important problem when com-
pared to those stemmed from the use of anti-TNFs. As a little
less than half of patients with psoriasis have joint manifes-
tations, Phase III studies evaluating anti-IL17 are underway,
some of them in their ﬁnal phase of evaluation. The strategy
of cytokine IL17 blockage in inﬂammatory arthritis and, in par-
ticular, in psoriasis, should pave the way for a new phase in
the arsenal of biological agents, especially considering that the
market should make available anti-TNF biogeneric drugs soon
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after or almost simultaneously with the introduction of anti-
IL17 for the treatment of inﬂammatory immune arthritis.11,12
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